103 related articles for article (PubMed ID: 31329518)
1. Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma.
Masuda K; Ishiki H; Oyamada S; Shimizu M; Kiuchi D; Satomi E
J Clin Oncol; 2019 Sep; 37(25):2293-2294. PubMed ID: 31329518
[No Abstract] [Full Text] [Related]
2. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
3. Reply to K. Masuda et al.
Fennell DA; Taylor P; Gilligan D; Nakano T; Scherpereel A; Pavlakis N; van Meerbeeck JP; Aerts JGJV; Nowak AK; Kindler H; Baas P
J Clin Oncol; 2019 Sep; 37(25):2294-2295. PubMed ID: 31329517
[No Abstract] [Full Text] [Related]
4. Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
Tranchant R; Quetel L; Montagne F; De Wolf J; Meiller C; De Koning L; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Lung Cancer; 2018 Dec; 126():15-24. PubMed ID: 30527180
[TBL] [Abstract][Full Text] [Related]
5. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
6. Recent insights emerging from malignant mesothelioma genome sequencing.
Carbone M; Gaudino G; Yang H
J Thorac Oncol; 2015 Mar; 10(3):409-11. PubMed ID: 25695218
[No Abstract] [Full Text] [Related]
7. The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Fizazi K; John WJ; Vogelzang NJ
Semin Oncol; 2002 Feb; 29(1):77-81. PubMed ID: 11836672
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
[TBL] [Abstract][Full Text] [Related]
9. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural mesothelioma: a phase II trial with docetaxel.
Vorobiof DA; Rapoport BL; Chasen MR; Abratt RP; Cronje N; Fourie L; McMichael G; Hacking D
Ann Oncol; 2002 Mar; 13(3):412-5. PubMed ID: 11996472
[TBL] [Abstract][Full Text] [Related]
11. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
Attanoos RL; Gibbs AR
Histopathology; 2008 Sep; 53(3):340-4. PubMed ID: 18647189
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
Steele JP; O'Doherty CA; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
Ann Oncol; 2001 Apr; 12(4):497-9. PubMed ID: 11398882
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
Fennell DA; McDowell C; Busacca S; Webb G; Moulton B; Cakana A; O'Byrne KJ; Meerbeeck JV; Donnellan P; McCaffrey J; Baas P
J Thorac Oncol; 2012 Sep; 7(9):1466-70. PubMed ID: 22895144
[TBL] [Abstract][Full Text] [Related]
17. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
Agarwal V; Lind MJ; Cawkwell L
Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
[TBL] [Abstract][Full Text] [Related]
18. LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice.
Hallur G; Tamizharasan N; Sulochana SP; Saini NK; Zainuddin M; Mullangi R
J Pharm Biomed Anal; 2018 Feb; 149():358-364. PubMed ID: 29145097
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
20. Surgery for malignant pleural mesothelioma: why, when and what?
Lang-Lazdunski L
Lung Cancer; 2014 May; 84(2):103-9. PubMed ID: 24602395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
